Charles River Laboratories EBITDA 2010-2025 | CRL
Charles River Laboratories annual and quarterly EBITDA history from 2010 to 2025. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Charles River Laboratories EBITDA for the quarter ending March 31, 2025 was $0.195B, a 7.71% decline year-over-year.
- Charles River Laboratories EBITDA for the twelve months ending March 31, 2025 was $0.788B, a 12.25% decline year-over-year.
- Charles River Laboratories 2024 annual EBITDA was $0.804B, a 13.67% decline from 2023.
- Charles River Laboratories 2023 annual EBITDA was $0.931B, a 2.46% decline from 2022.
- Charles River Laboratories 2022 annual EBITDA was $0.955B, a 11.63% increase from 2021.
| Charles River Laboratories Annual EBITDA (Millions of US $) |
|
|---|---|
| 2024 | $804 |
| 2023 | $931 |
| 2022 | $955 |
| 2021 | $855 |
| 2020 | $668 |
| 2019 | $549 |
| 2018 | $493 |
| 2017 | $419 |
| 2016 | $364 |
| 2015 | $301 |
| 2014 | $276 |
| 2013 | $258 |
| 2012 | $265 |
| 2011 | $280 |
| 2010 | $120 |
| 2009 | $273 |
| Charles River Laboratories Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2025-03-31 | $195 |
| 2024-12-31 | $149 |
| 2024-09-30 | $206 |
| 2024-06-30 | $238 |
| 2024-03-31 | $211 |
| 2023-12-31 | $213 |
| 2023-09-30 | $230 |
| 2023-06-30 | $243 |
| 2023-03-31 | $245 |
| 2022-12-31 | $241 |
| 2022-09-30 | $226 |
| 2022-06-30 | $264 |
| 2022-03-31 | $224 |
| 2021-12-31 | $240 |
| 2021-09-30 | $224 |
| 2021-06-30 | $206 |
| 2021-03-31 | $185 |
| 2020-12-31 | $190 |
| 2020-09-30 | $192 |
| 2020-06-30 | $134 |
| 2020-03-31 | $152 |
| 2019-12-31 | $161 |
| 2019-09-30 | $145 |
| 2019-06-30 | $129 |
| 2019-03-31 | $115 |
| 2018-12-31 | $144 |
| 2018-09-30 | $128 |
| 2018-06-30 | $120 |
| 2018-03-31 | $101 |
| 2017-12-31 | $96 |
| 2017-09-30 | $108 |
| 2017-06-30 | $113 |
| 2017-03-31 | $102 |
| 2016-12-31 | $105 |
| 2016-09-30 | $93 |
| 2016-06-30 | $90 |
| 2016-03-31 | $76 |
| 2015-12-31 | $76 |
| 2015-09-30 | $80 |
| 2015-06-30 | $80 |
| 2015-03-31 | $66 |
| 2014-12-31 | $67 |
| 2014-09-30 | $73 |
| 2014-06-30 | $76 |
| 2014-03-31 | $60 |
| 2013-12-31 | $54 |
| 2013-09-30 | $68 |
| 2013-06-30 | $68 |
| 2013-03-31 | $67 |
| 2012-12-31 | $60 |
| 2012-09-30 | $63 |
| 2012-06-30 | $74 |
| 2012-03-31 | $68 |
| 2011-12-31 | $67 |
| 2011-09-30 | $65 |
| 2011-06-30 | $80 |
| 2011-03-31 | $68 |
| 2010-12-31 | $-32 |
| 2010-09-30 | $39 |
| 2010-06-30 | $60 |
| 2010-03-31 | $54 |
| 2009-12-31 | $69 |
| 2009-09-30 | $69 |
| 2009-06-30 | $74 |
| 2009-03-31 | $62 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $8.690B | $4.050B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $147.134B | 27.29 |
| CVS Health (CVS) | United States | $76.787B | 9.54 |
| Elevance Health (ELV) | United States | $65.099B | 8.76 |
| Cencora (COR) | United States | $56.279B | 19.58 |
| DiDi Global (DIDIY) | China | $25.745B | 27.35 |
| Labcorp Holdings (LH) | United States | $22.177B | 17.50 |
| Natera (NTRA) | United States | $18.966B | 0.00 |
| BioMerieux (BMXMF) | France | $17.681B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $15.851B | 0.00 |
| ICON (ICLR) | Ireland | $15.102B | 14.53 |
| CochLear (CHEOY) | Australia | $13.402B | 0.00 |
| Solventum (SOLV) | United States | $12.933B | 13.69 |
| Medpace Holdings (MEDP) | United States | $12.571B | 33.27 |
| Revvity (RVTY) | United States | $12.220B | 21.03 |
| Viatris (VTRS) | United States | $11.044B | 3.79 |
| Avantor (AVTR) | United States | $9.683B | 14.07 |
| Sonic Healthcare (SKHHY) | Australia | $9.143B | 0.00 |
| HealthEquity (HQY) | United States | $8.305B | 36.38 |
| Caris Life Sciences,�Inc (CAI) | United States | $7.515B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $5.066B | 29.83 |
| BrightSpring Health Services (BTSG) | United States | $3.609B | 33.11 |
| Sotera Health (SHC) | United States | $3.491B | 19.84 |
| Surgery Partners (SGRY) | United States | $2.725B | 35.43 |
| Organon (OGN) | United States | $2.654B | 2.82 |
| Concentras Parent (CON) | United States | $2.520B | 14.56 |
| Alignment Healthcare (ALHC) | United States | $2.327B | 0.00 |
| GeneDx Holdings (WGS) | United States | $2.278B | 87.72 |
| Progyny (PGNY) | United States | $1.981B | 43.60 |
| GoodRx Holdings (GDRX) | United States | $1.786B | 35.71 |
| PACS (PACS) | United States | $1.782B | 0.00 |
| Premier (PINC) | United States | $1.744B | 13.23 |
| Ardent Health (ARDT) | United States | $1.582B | 6.74 |
| Teladoc Health (TDOC) | United States | $1.439B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.226B | 0.00 | |
| Pediatrix Medical (MD) | United States | $1.080B | 8.22 |
| QDM (QDMI) | Hong Kong, SAR China | $0.997B | 342.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.970B | 0.00 |
| Agilon Health (AGL) | United States | $0.853B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.758B | 7.10 |
| CareDx (CDNA) | United States | $0.712B | 11.12 |
| Embecta (EMBC) | United States | $0.686B | 4.62 |
| Nutex Health (NUTX) | United States | $0.528B | 7.99 |
| InnovAge Holding (INNV) | United States | $0.518B | 0.00 |
| Omada Health (OMDA) | $0.495B | 0.00 | |
| SBC Medicals (SBC) | United States | $0.493B | 0.00 |
| LifeMD (LFMD) | United States | $0.486B | 0.00 |
| So-Young (SY) | China | $0.471B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.464B | 10.45 |
| Sonida Senior Living (SNDA) | United States | $0.461B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.405B | 0.00 |
| Enhabit (EHAB) | United States | $0.342B | 28.12 |
| Oncology Institute (TOI) | United States | $0.328B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.284B | 0.00 |
| Beauty Health (SKIN) | United States | $0.226B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.192B | 0.00 |
| DocGo (DCGO) | United States | $0.149B | 24.33 |
| Sera Prognostics (SERA) | United States | $0.122B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.090B | 0.00 |
| KindlyMD (NAKA) | United States | $0.080B | 0.00 |
| Biodesix (BDSX) | United States | $0.065B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.063B | 0.00 |
| NeueHealth (NEUE) | United States | $0.060B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.044B | 0.00 |
| ModivCare (MODV) | United States | $0.044B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.042B | 0.00 |
| OSR Holdings (OSRH) | United States | $0.019B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.011B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.009B | 0.00 | |
| SeaStar Medical Holding (ICU) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.006B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |